This document summarizes an innovative malaria vaccine in development. It uses a whole organism approach with Plasmodium berghei that has shown over 90% protection in early trials. The vaccine aims to address current limitations like lack of efficacy, safety concerns, and inability to prevent the most common parasite, P. vivax. It has received over $2 million in funding and prizes. Clinical trials are expected to begin by late 2015 with the goal of market entry by 2025. Near term, a cryopreservation technology for vaccine storage and delivery is targeting market entry by 2016 with projected annual revenues of $100,000.

1. Photo credit:: PATH Malaria Vaccine inniciative
REVOLUTiONiZiNG
MALARiA
VACCiNATiON

2. Company
Research
spin-off of IMM
founded in 2013
Faculdade de Medicina da
Universidade de Lisboa,
Centro Hospitalar Lisboa-Norte,
1649 – 028
Lisboa, Portugal
MCRC Lisboa
NIPC: 513226478

3. Scientific advisory board
Prof. Dr. Robert W. Saurwein
Prof. Chris J. Janse
Prof. Sangeeta N. Bhatia
Dr. Shahid M. Khan
Dr. Inigo A-Barturen
Business development
advisorsFounders

4. Validation
 Phase I funding
100 thousand US$
(November 2010)
 Phase II funding
1.2 million US$
(November 2013)
 Supplement to
Phase II funding
320 thousand US$
(December 2014)
1st
IBERIAN project to receive
Phase II funding by BMGF

5. Business development
 1st
prize in BES
innovation contest
(December 2013)
80 thousand US$
 Honorable mention in
2013 BGI IUL-MIT
competition
 Finalist of the 6th
Universal Biotech
innovation Prize
 Finalist of the XII
EVERIS Foundation

6. Stakeholders

7. Problem
MALARIA
 2.5 billion people at risk
of contracting malaria
 700 thousand deaths
every year
 12 billion US$ in lost
GDP of endemic countriesNO EFFECTIVE VACCINE
AVAILABLE
Photo credit: Antonio M. Mendes
Most advanced
candidate only affords
~36% protection against
a single parasite species

8. 4.5 billion
US$ global
market
 Humanitarian market:
(estimated value: 3 billion US$)
 Private market:
(estimated value: 700 million US$)
 Tourist & military
market:
(estimated value: 800 million US$)
Market potential
Photo credit: NYtimes

9. Do not target the most prevalent
parasite, P. vivax
Serious safety
concerns
Vaccine Approaches
Extremely high
dosages
Whole
organism
vaccines
Shown to confer
>90% sterile
protection against a
new infection in
Phase I/IIa trialsMandatory high biosafety BSL3
production facilities

10. Photo credit: worldnaturephoto.com
Plasmodium
berghei
Uniqueness
A SAFE & VERSATILE
WHOLE-ORGANISM PLATFORM
FOR VACCINATION AGAINST
MULTIPLE HUMAN
PARASITES
PCT/IB2013/053050

11. Phase I/IIa Clinical trials
 Submission of
authorization
request to
regulatory
authorities
Efficacy studies in non-human
primate model
Pharmacological studies in
rabbit model
 Expected start
date: End of 2015

12. Strategy
 Vaccine
Clinical
Development
(Market entry: 2025)
 Production &
delivery
technology
(Market entry: 2016)

13. Production & delivery
 Establishment of
cell culture-based
production of
sporozoites
 Development of a
vaccine
cryopreservation
system

14. Financial returns
 2016
onwards:
Cryopreservation
technology
100 thousand
US$ / year
 2020 - 2015:
Vaccination platform
Licensing / selling
46 million US$

15. LET’S PUT AN
END TO MALARiA
Photo credit: Antonio M. Mendes
Contact: antoniomendes@medicina.ulisboa.pt